Numerous active and planned clinical trials are investigating the safety of adeno-associated virus (AAV)-mediated gene therapy for inherited retinal diseases (IRDs).

Treatment-emergent adverse events (TEAEs) are related to the delivery method, vector system, and underlying retinal condition.

Emphasis should be placed on minimizing subretinal- and intravitreal-related complications, the most common cause of adverse events in completed gene replacement trials.

Perioperative steroids are used to manage AAV immunogenicity.